Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Peking Union Medical College
- Trial code
- NCT07109765
- Record updated
- 7 August 2025
- Original description
This single-center, prospective, observational study aimed to evaluate the efficacy and safety of Secukinumab in treating moderate-to-severe hidradenitis suppurativa (HS). The study was conducted from June 1, 2025, to June 1, 2026, and all participants were treated at the Department of Dermatology, Peking Union Medical College Hospital. The study was approved by the Clinical and Research Ethics Committee of the Chinese Academy of Medical Sciences, Peking Union Medical College Hospital (Ethics Approval No. I-24PJ1844). All procedures involving human participants adhered to the Declaration of Helsinki. Written informed consent form was signed and obtained from the participant.Read full original descriptionShow less
Real-World Evaluation of Secukinumab in Moderate-to-Severe Hidradenitis Suppurativa
This single-center, prospective, observational study aimed to evaluate the efficacy and safety of Secukinumab in treating moderate-to-severe hidradenitis suppurativa (HS). The study was conducted from June 1, 2025, to June 1, 2026, and all participants were treated at the Department of Dermatology, Peking Union Medical College Hospital. The study was approved by the Clinical and Research Ethics Committee of the Chinese Academy of Medical Sciences, Peking Union Medical College Hospital (Ethics Approval No. I-24PJ1844). All procedures involving human participants adhered to the Declaration of Helsinki. Written informed consent form was signed and obtained from the participant.
Inclusion: age ≥18 years; diagnosis of moderate-to-severe HS with Hurley stage II or III; Disease duration of ≥6 months, presence of at least one draining tunnel or two inflammatory nodules; inadequate response to prior treatments, such as antibiotics, isotretinoin, or TNF inhibitors.
Exclusion: active infections (e.g., viral hepatitis, active tuberculosis); severe organ dysfunction (e.g., hepatic or renal failure); any other conditions that might affect study results; use of other biologics or systemic immunosuppressants within the past three months.